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Background. GII.4 noroviruses are a signiﬁcant source of acute gastroenteritis worldwide, causing the majority
of human norovirus outbreaks. Evolution of the GII.4 major capsid protein occurs rapidly, resulting in the emer-
gence of new strains that produce successive waves of pandemic disease. A new pandemic isolate, GII.4 2012
Sydney, largely replaced previously circulating strains in late 2012. We compare the antigenic properties of GII.4
2012 Sydney with previously circulating strains.
Methods. To determine whether GII.4-2012 Sydney is antigenically different from recently circulating strains
GII.4-2006 Minerva and GII.4-2009 New Orleans in previously identiﬁed blockade epitopes, we compared reactivity
and blockade proﬁles of GII.4-2006, GII.4-2009, and GII.4-2012 virus-like particles in surrogate neutralization/
blockade assays using monoclonal antibodies and human polyclonal sera.
Results. Using monoclonal antibodies that map to known blockade epitopes in GII.4-2006 and GII.4-2009 and
human outbreak polyclonal sera, we demonstrate either complete loss or signiﬁcantly reduced reactivity and block-
ade of GII.4.2012 compared to GII.4-2006 and GII.4-2009.
Conclusions. GII.4-2012 Sydney is antigenically different from GII.4-2006 Minerva and GII.4-2009 New
Orleans in at least 2 key blockade epitopes. Viral evolution in key potential neutralization epitopes likely allowed
GII.4-2012 to escape from human herd immunity and emerge as the new predominant strain.
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Noroviruses are a leading cause of acute gastroenteritis,
resulting in approximately 21 million infections in the
United States annually [1]. The highly heterogeneous
human noroviruses are divided into 2 principal gen-
ogroups designated GI and GII, which are further sub-
divided into 9 and 21 genotypes, respectively [2, 3]. The
GII.4 noroviruses are responsible for >70% of all noro-
virus outbreaks [4]. Norovirus disease patterns in
human populations include epidemic outbreaks of
disease every 2–3 years, punctuated by the emergence
of an antigenically distinct GII.4 strain that appears to
escape human herd immunity to the previous circulat-
ing strain [5–8]. The ﬁrst major GII.4 norovirus pan-
demic was associated with the GII.4-1997 US95/96
strain [9, 10], which was replaced in 2002 with GII.4-
2002 Farmington Hills [11]. GII.4-2002 was then re-
placed in 2004 by the Hunter strain [12–14]. In 2006,
GII.4-2006 Minerva replaced Hunter [13, 15, 16] and
was the predominant strain until 2009 when it was
gradually replaced with GII.4-2009 New Orleans [17].
In March 2012, a new strain, called GII.4-2012 Sydney,
was ﬁrst described, and by November 2012, it had re-
placed GII.4-2009 as the primary norovirus strain in
most countries in the northern hemisphere [18, 19].
Noroviruses are single-stranded, positive sense RNA
viruses that belong to the family Caliciviridae. The nor-
ovirus genome is approximately 7.5 kb and contains 3
open reading frames (ORFs). ORF1 encodes the non-
structural proteins, ORF2 encodes the VP1 major
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capsid protein, and ORF3 encodes the VP2 minor capsid
protein [20]. The P2 subdomain of VP1 contains potential neu-
tralizing antibody epitopes and interacts with histoblood group
antigens (HBGAs), which are a diverse family of carbohydrates
and serve as putative receptors for norovirus entry [6, 7, 21–27].
HBGAs are differentially expressed in humans and differentially
bound by norovirus strains [20, 21, 25, 27, 28].
There is currently no cell culture or small animal model
available to study human noroviruses, slowing progress toward
understanding the mechanisms of protective immunity, virus
evolution, and the development of an effective vaccine.
However, virus-like particles (VLPs), which are morphological-
ly and antigenically comparable to native virions, serve as a
virus surrogate, and, in conjunction with bioinformatics and
surrogate neutralization assays, provide a good model to study
questions regarding viral evolution and human immunity,
which will ultimately inform vaccine design [6–8, 29].
Using human and mouse monoclonal antibodies and time-
ordered wild-type and chimeric GII.4 VLPs, we and others
have previously shown that the emergence of these new pan-
demic strains is often associated with alterations in GII.4 block-
ade epitopes mapped to the surface of the major capsid protein
P2 subdomain [5–8, 30–33]. In this manuscript, we demon-
strate that the emergence of GII.4-2012 Sydney is associated
with changes in major blockade epitopes, especially epitopes
A [6] and D [5], that lead to altered antigenicity as compared to
GII.4-2009 New Orleans.
MATERIALS ANDMETHODS
Virus-like Particles
A synthetically-derived outbreak GII.4-2012 ORF2 comple-
mentary DNA was synthesized (BioBasic), and inserted into
the Venezuelan equine encephalitis virus 3526 replicon vector
(VRP-3526). For GII.4-2006 and GII.4-2009 VLPs, virus repli-
con particles (VRPs) were produced and inoculated onto baby
hamster kidney (BHK) cells as previously described [5]. For
GII.4-2012, VLPs were expressed from Venezuelan equine en-
cephalitis replicon vector RNA after electroporation of BHK
cells and puriﬁed as described previously [6, 8]. Structural in-
tegrity of VLPs was conﬁrmed by electron microscopy, enzyme
immunoassay, and carbohydrate binding [5].
HBGA-VLP Binding Assay
HBGA binding assays were performed as previously described [6,
21]. In brief, synthetic HBGAs or pig gastric mucin type III
(PGM; Sigma Chemicals) was diluted to 10 µg/mL and coated
onto plates. Two micrograms/mL VLPs were added and detected
by polyclonal rabbit sera and then antirabbit immunoglobulin G
(IgG)–horseradish peroxidase (HRP) (GE Healthcare) followed
by One-Step Ultra TMB EIA HRP substrate solution (Thermo-
Fisher). Data are the average of 3 replicates with similar results
from at least 2 independent experiments. Positive reactivity is
deﬁned as a mean optical density (OD) >3 times the background
binding signal.
Enzyme Immunoassays
Mouse and human monoclonal antibody (mAb) reactivity was
determined by EIA, as reported [5, 7]. In brief, 1 µg/mL VLP in
phosphate-buffered saline was coated onto plates, followed by
addition of 1 µg/mL puriﬁed IgG and then antimouse or anti-
human IgG-HRP (GE Healthcare) followed by One-Step Ultra
TMB EIA HRP substrate solution. Data are the average of 3
replicates from at least 2 independent experiments. Positive re-
activity is deﬁned as a mean OD 450 nm >0.2 after background
subtraction [8].
VLP-Carbohydrate Ligand-Binding Antibody Blockade Assays
PGM contains HBGAs α-1,2-fucose (H antigen) and α-1,4-
fucose (Lewis antigen) [7, 21, 34] and has been validated as a
substrate for norovirus VLP antibody-blockade assays [5, 7].
Blockade assays were performed as previously described [8].
VLPs bound to PGM or biotinylated B were detected by rabbit
anti-GII.4 norovirus polyclonal sera. The percentage of control
binding was deﬁned as the VLP-ligand binding level in the
presence of test antibody or sera compared to the binding level
in the absence of antibody multiplied by 100 [7, 35]. All anti-
bodies were tested for blockade potential at 2-fold serial dilu-
tions ranging from 0.004 to 2 µg/mL for mouse mAbs, from
0.008 to 16 µg/mL for human mAbs, or from 0.008% to 1% for
human serum. Data shown are the average of at least 2 repli-
cates and are representative of similar data from at least 2 inde-
pendent trials. Sigmoidal dose response analysis was performed
as previously described [8]. EC50 values (the antibody or serum
concentration required to block 50% of the VLP-carbohydrate
binding) amongVLPswere compared using 1-way analysis of var-
iance with Dunnett posttest. P < .05 was considered signiﬁcant.
Hybridoma Production, IgG Puriﬁcation, and GII.4 Outbreak
Serum Samples
Mouse and human mAbs were produced and puriﬁed as de-
scribed previously by our group [5, 29]. De-identiﬁed human con-
valescent serum samples collected from 8 subjects infected with
GII.4-2009, as previously described, were used in this study [8].
RESULTS
GII.4 noroviruses undergo genetic changes over time, which
are associated with changes in antigenicity [29]. We previously
identiﬁed 3 GII.4 blockade epitopes in VP1, designated A, D,
and E, which are altered in GII.4-2012 and other contemporary
strains and affect GII.4 norovirus antigenic proﬁles [5–8]
(Figure 1). In early strains, epitope A appears immunodomi-
nant, accounting for 40%–55% of the total blockade response
[7, 9]; GII.4-2009 and GII.4-2012 share 4 common residues but
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have 2 amino acid changes at P294 T and A368E. Epitope D
shares 2 residues between GII.4-2009 and GII.4-2012, with dif-
ferences at S393G and P396H. Epitope E has one differential
residue between GII.4-2012 and GII.4-2009, a I413 T change.
To test the impact of these sequence changes on antigenicity,
we produced GII.4-2012 Sydney and chimeric VLPs. Overall,
GII.2-2012 exhibited decreased EIA binding to all synthetic
HBGAs tested compared to GII.4-2009 (Figure 2). Next, we
compared EIA reactivity and blockade ability of mAbs and
human outbreak sera between GII.4-2012 and previous pre-
dominant strains GII.4-2009 and GII.4-2006.
GII.4-2006 Mouse Monoclonal EIA Cross-Reactivity and
Blockade Response
We previously characterized a set of GII.4-2006 mouse mAbs,
all of which exhibit strong EIA reactivity with GII.4-2006 and
GII.4-2009 and are blockade antibodies that target overlapping
residues across epitope A [6–8, 29]. To determine whether
GII.4-2006 mouse mAbs are able to distinguish GII.4-2012
from previous GII.4 strains, we compared 5 GII.4-2006 (G2,
G3, G4, G6, G7) mouse mAbs for EIA reactivity with GII.4-
2012, GII.4-2006, and GII.4-2009 VLPs. By EIA, GII.4-2012
did not bind with GII.4-2006-G3 and G4 mAbs (Figure 3A),
whereas reactivity with GII.4-2006-G2, G6, and G7 mAbs was
signiﬁcantly reduced (P < .05) 1.8- to 4.5-fold compared with
GII.4-2006 and GII.4-2009 (Figure 3A).
Blockade is a more sensitive measure of antigenic variation
and, unlike EIA, can measure potential functional differences in
antigenicity that correlate with protective immunity in vivo [36,
37]. Three GII.4-2006 blockade mouse mAbs that map to
epitope A demonstrated EIA reactivity with GII.4-2012 (GII.4-
2006-G2, G6, and G7). To examine functionally relevant anti-
genic differences between GII.4-2012 and previous strains, we
performed surrogate neutralization blockade assays. GII.4-
2006-G2, although able to block both GII.4-2006 and GII.4-
2009 VLPs, lost the ability to block GII.4-2012 VLP interaction
with HBGA (Figure 3B). GII.4-2006-G6 and G7 mAbs were both
able to block GII.4-2012 VLP interaction with HBGA, but EC50
values were signiﬁcantly reduced (3.9- to 6.3-fold) compared with
GII.4-2006 and GII.4-2009 VLPs (Figure 3C and 3D). Of 5
Figure 1. GII.4 norovirus structure and genetic variability in blockade epitopes. A, Schematic representation of the norovirus genome. Open reading
frame (ORF) 1 encodes the nonstructural proteins, ORF2 encodes the major capsid protein, and ORF3 encodes the minor capsid protein. The major capsid
protein is divided into the shell and the P1 and P2 subdomains. B, Blockade epitopes for GII.4 noroviruses. A structural model of a GII.4 norovirus P2 dimer
indicates the location of previously identiﬁed blockade epitopes A, D, and E. C, GII.4-2012 changes in evolving blockade epitopes. Amino acid sequences
from GII.4-2006, GII.4-2009, and GII.4-2012 were aligned and changes occurring in epitopes A, D, and E are noted in the tables. D, Previously reported
epitope binding speciﬁcity of GII.4-2006 and GII.4-2009 mouse monoclonal antibodies (mAbs) and GII.4 human mAbs.
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GII.4-2006 blockade mouse mAbs that target epitope A, only 2
(G6, G7) retained limited EIA and blockade ability against GII.4-
2012 VLPs, and both of these were signiﬁcantly reduced.
GII.4-2009 Mouse Monoclonal EIA Cross-Reactivity and
Blockade Response
To further compare the impact of epitope A changes on GII.4-
2012 antigenic structure and function, we evaluated GII.4-2012
reactivity with 4 GII.4-2009 blockade mouse mAbs. Previous
work demonstrated that mAbs NO37 and NO52 target epitope
A, but the binding sites for mAbs NO66 and NO224 have not
yet been mapped on the structure [8]. NO37 cross-reacts with
GII.4-2006 and GII.4-2009 [8], but does not bind GII.4-2012
(Figure 4A). The other NO antibodies tested react with GII.4-
2009 but not GII.4-2006 [8]. NO52 and NO224 binding to
GII.4-2012 were signiﬁcantly reduced (2.75- to 3.9-fold, respec-
tively) compared to GII.4-2009. NO66 failed to react by EIA
with GII.4-2012 under these treatment conditions (Figure 4A).
In addition, we tested the GII.4-2009 mouse mAbs that bind
GII.4-2012 in EIA (NO52 and NO224) for blockade potential
against this strain. Both NO52 and NO224 were able to block
GII.4-2012 (Figure 4B and 4C). Interestingly, NO52 blocked
GII.4-2012 signiﬁcantly more efﬁciently than the homotypic
GII.4-2009 VLP (Figure 4B), indicating that this mAb may
target a unique motif within epitope A compared with other
epitope A–targeting antibodies. EC50 blockade titers for GII.4-
2012 and GII.4-2009 by NO224 were not signiﬁcantly different
(Figure 4C). These results support our data from GII.4-2006
mAbs, demonstrating that antigenicity between GII.4-2012 and
previously circulating strains is signiﬁcantly different at epitope
A. These results also conﬁrm previous ﬁndings that epitope A
mAbs likely engage overlapping, yet distinct epitope residues.
Human Monoclonal Antibody EIA Cross-Reactivity and
Blockade Response
Although mouse mAbs provide an excellent tool to examine
targeted, strain-speciﬁc norovirus antibody responses, it is pos-
sible that the immune systems of mice and humans engage nor-
ovirus epitopes differently. Therefore, we examined whether
human mAb EIA reactivity and blockade responses were also
able to differentiate between GII.4-2012 and ancestral strains.
We previously characterized 4 blockade human mAbs, which
recognize either GII.4-2006 or GII.4-2009, or both (NVB 43.9,
NVB 71.4, NVB 97, NVB 111) [5]. Two of these mAbs map to
epitope A (NVB 43.9, NVB 111) and another maps to epitope
D (NVB 97) [5]. NVB 71.4 recognizes a conserved GII.4 block-
ade epitope across time-ordered strains that has not yet been
mapped onto the structure. We ﬁrst tested these GII.4 blockade
human mAbs for EIA reactivity with GII.4-2012. Consistent
with a previous report, NVB 43.9, NVB 71.4, and NVB 97 rec-
ognize GII.4-2006 and GII.4-2009, whereas NVB 111 binds
only GII.4-2006 [5]. When we examined reactivity of these
human mAbs with GII.4-2012, we found that NVB 43.9 and
NVB 111 (epitope A), and NVB 97 (epitope D) lost EIA
Figure 2. GII.4-2012 histoblood group antigen (HBGA) binding. Virus-like particles (VLPs) representing GII.4-2006, GII.4-2009, and GII.4-2012 strains
were assayed for their ability to bind synthetic biotinylated HBGAs or pig gastric mucin type III (PGM). The mean optical density (OD) 450 nm was calculat-
ed and graphed. Error bars represent SEM. VLP reactivity is deﬁned as a positive signal >3 times the background binding, indicated by the dashed line.
Abbreviations: CHO, carbohydrate; Le, Lewis.
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reactivity with GII.4-2012 (Figure 5A). NVB 71.4 retained
binding to GII.4-2012 similar to levels seen with GII.4-2006
and GII.4-2009 (Figure 5A). These results corroborate the im-
portance of epitope A changes in antibody recognition of
GII.4-2012. In addition, loss of binding to the epitope D mAb
indicates that this epitope has also evolved in the GII.4-2012
strain.
Next, we determined whether human blockade mAbs could
further distinguish between emergent GII.4-2012 and contem-
porary GII.4-2009 strains. GII.4-2012 was only recognized by
one human blockade mAb, NVB 71.4. This broadly cross-
reactive and blocking antibody is capable of preventing HBGA
binding with GII.4 strain VLPs from GII.4-1987 through
GII.4-2009 [5]. When tested for blockade response against GII.4-
2012, NVB 71.4 weakly blocked this strain, with an EC50 signif-
icantly higher than for GII.4-2006 and GII.4-2009 (Figure 5B).
We also evaluated NVB 97 blockade activity against GII.4-2012
despite its inability to bind GII.4-2012 by single dilution EIA.
NVB 97 targets epitope D, another previously identiﬁed GII.4
blockade epitope [5]. Corroborating EIA data, NVB 97 was not
able to block GII.4-2012 VLP-binding ligand interaction by
blockade assay (Figure 5C). Overall, human mAb blockade data
Figure 3. GII.4-2006 mouse monoclonal antibody (mAb) enzyme immunoassay (EIA) reactivity and blockade response against GII.4-2012. A, Mouse
mAbs (1 µg/mL) against GII.4-2006 (G2, G3, G4, G6, and G7) were assayed for ability to react with GII.4-2006, GII.4-2009, and GII.4-2012 virus-like particles
(VLPs) by EIA. The mean optical density (OD) 450 nm was calculated and graphed. Error bars represent SEM. *Reactivity is signiﬁcantly different from that
of the homotypic GII.4-2006 VLP. Reactivity is deﬁned as a positive signal >0.2 by EIA, represented by the dashed line. VLP reactivity below the dashed line
is considered nonreactive. B–G, Mouse mAbs against GII.4-2006 (G2, G6, G7) were assayed for ability to block GII.4-2006, GII.4-2009, and GII.4-2012 VLP
interaction with carbohydrate ligand pig gastric mucin type III (B–D ) or biotinylated B (E–G ). The mean percentage of control binding (percent of the VLP
bound to carbohydrate ligand in the presence of an antibody compared to the amount of VLP bound with no antibody present) of each VLP was ﬁt with a
sigmoidal curve, and the mean EC50 (µg/mL) blockade titers (the antibody concentration at which 50% of VLP-PGM binding is blocked) for GII.4-2006, GII.4-
2009, and GII.4-2012 were calculated. Error bars represent 95% conﬁdence intervals. *Mean EC50 blockade titer for the test VLP is signiﬁcantly different
from the mean EC50 for GII.4-2006 (P < .05). Monoclonal antibodies that did not block a particular VLP were assigned an EC50 of 4 µg/mL for statistical anal-
ysis and are shown on the graph by data points above the upper limit of detection (dashed line). Statistics for both EIA and blockade assays were calculat-
ed by 1-way analysis of variance with Dunnett posttest.
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Figure 4. GII.4-2009 mouse monoclonal antibody (mAb) enzyme immunoassay (EIA) reactivity and blockade response against GII.4-2012. A, Mouse
mAbs (1 µg/mL) against GII.4-2009 (NO37, 52, 66, and 224) were assayed for ability to react with GII.4-2006, GII.4-2009, and GII.4-2012 VLPs by EIA. The
mean optical density (OD) 450 nm was calculated and graphed. Error bars represent SEM. *Reactivity is signiﬁcantly different from that of the homotypic
GII.4-2009 virus-like particle (VLP). Reactivity is deﬁned as a positive signal >0.2 by EIA, represented by the dashed line. VLP reactivity below the dashed
line is considered nonreactive. B–E, Mouse mAbs against GII.4-2009 (NO 52, 224) were assayed for ability to block GII.4-2006, GII.4-2009, and GII.4-2012
VLP interaction with carbohydrate ligand pig gastric mucin type III (B and C ) or biotinylated B (D–E ). The mean percentage of control binding (percentage
of the VLP bound to carbohydrate ligand in the presence of an antibody compared to the amount of VLP bound with no antibody present) of each VLP was
ﬁt with a sigmoidal curve, and the mean EC50 (µg/mL) blockade titers (the antibody concentration at which 50% of VLP-PGM binding is blocked) for GII.4-
2006, GII.4-2009, and GII.4-2012 were calculated. Error bars represent 95% conﬁdence intervals. *Mean EC50 blockade titer for the test VLP is signiﬁcantly
different from the mean EC50 for GII.4-2009 (P < .05). Monoclonal antibodies that did not block a particular VLP were assigned an EC50 of 4 µg/mL for statis-
tical analysis and are shown on the graph by data points above the upper limit of detection (dashed line). Statistics for both EIA and blockade assays were
calculated by 1-way analysis of variance with Dunnett posttest.
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Figure 5. GII.4 human monoclonal antibody (mAb) enzyme immunoassay (EIA) reactivity and blockade response against GII.4-2012. A, Human mAbs
against GII.4 norovirus (1 µg/mL) were assayed for ability to react with GII.4-2006, GII.4-2009, and GII.4-2012 virus-like particles (VLPs) by EIA. The mean
optical density (OD) 450 nm was calculated and graphed. Error bars represent SEM. *Reactivity is signiﬁcantly different from that of the GII.4-2009 VLP. Re-
activity is deﬁned as a positive signal >0.2 by EIA, represented by the dashed line. VLP reactivity below the dashed line is considered nonreactive. B–E,
Human mAbs against GII.4 noroviruses were assayed for ability to block GII.4-2006, GII.4-2009, and GII.4-2012 VLP interaction with carbohydrate ligand
pig gastric mucin type III (B and C ) or biotinylated B (D and E ). The mean percentage of control binding (percentage of the VLP bound to carbohydrate
ligand in the presence of an antibody compared to the amount of VLP bound with no antibody present) of each VLP was ﬁt with a sigmoidal curve, and the
mean EC50 (µg/mL) blockade titers (the antibody concentration at which 50% of VLP-PGM binding is blocked) for GII.4-2006, GII.4-2009, and GII.4-2012
were calculated. Error bars represent 95% conﬁdence intervals. *Mean EC50 blockade titer for the tested VLP is signiﬁcantly different from the mean EC50
for GII.4-2009 (P < .05). Monoclonal antibodies that did not block a particular VLP at the highest mAb concentration tested were assigned an EC50 of 2
times the upper limit tested in µg/mL for statistical analysis and are shown on the graph by data points above the upper limit of detection (dashed line).
Statistics for both EIA and blockade assays were calculated by 1-way analysis of variance with Dunnett posttest.
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are consistent with mouse mAb blockade data, demonstrating
that GII.4-2012 is antigenically distinct in major blockade epi-
topes from previously circulating contemporary strains GII.4-
2006 and GII.4-2009.
Mapping of GII.4-2012 Amino Acids Involved in Epitope A
Antigenic Differences
To more speciﬁcally map amino acids important for antigenic
differences between GII.4-2009 and GII.4-2012, 3 epitope A
chimeras between GII.4-2009 and GII.4-2012 were constructed,
where residues from GII.4-2009 were inserted into the GII.4-
2012 background (2012.T294P, 2012.E368A, and 2012.09A).
We performed blockade assays using epitope A targeting anti-
bodies against these chimeras and compared them to parental
strain blockade data. Overall, data show that GII.4-2012 residue
368E is important for the antigenic differences in epitope A
between GII.4-2009 and GII.4-2012, as this residue impacted
the blockade ability of all 8 epitope A–targeting mAbs tested
(2006-G2, G3, G4, G6, G7, NO37, NO52, and NVB 43.9), and
representative data are shown (Figure 6A). Residue 294 T was
also important, synergistically contributing with 368E to the
difference in blockade response for 4 of 8 mAbs (2006-G3,
NO37, NO52, NVB 43.9), and representative data are shown
(Figure 6B). Importantly, blockade proﬁles between GII.4-2009
and GII.4-2012.09A were different for some antibodies
(Figure 6A), indicating that there are other residues not includ-
ed in the deﬁned epitope A that contribute to antigenicity
changes between GII.4-2009 and GII.4-2012.
GII.4-2009 Outbreak Human Sera Against GII.4-2012
Blockade results with mAbs demonstrated differences between
GII.4-2009 and GII.4-2012 in epitopes A and D, but mAb data
do not represent the total antibody response. To determine if
the polyclonal antibody response is different between GII.4-
2009 and GII.4-2012 and to what degree epitope A accounts for
any differences, we tested the blockade activity of GII.4-2009
outbreak convalescent human sera from 8 individuals against
GII.4-2009, GII.4-2012, and GII.4-2012.09A VLPs. EC50 titers
demonstrated that signiﬁcantly more sera was necessary to
block GII.4-2012 (0.066%) and GII.4-2012.09A (0.048%) com-
pared to GII.4-2009 (0.021%) (Figure 7). This demonstrates
that only approximately 30% of the blockade against GII.4-
2009 is retained against GII.4-2012, and at least 11% of the de-
creased response is due to changes in epitope A. Individually, it
took signiﬁcantly more sera to block GII.4-2012 compared to
GII.4-2009 in 7 of 8 serum samples (Supplementary Figure 1A–
G) and signiﬁcantly less sera to block in 1 of 8 serum samples
(Supplementary Figure 1H). In 4 of 8 serum samples (Supple-
mentary Figure 1B, C, E, and H), epitope Awas responsible for a
signiﬁcant change in blockade, accounting for between 21% and
100% of the change.
DISCUSSION
GII.4 noroviruses are the principal cause of epidemic norovirus
gastroenteritis in human populations. The GII.4 genotype un-
dergoes epochal evolution whereby a predominant circulating
Figure 6. Monoclonal antibody (mAb) blockade of chimeric GII.4-2012 virus-like particles (VLPs). Mouse and human epitope A–targeting monoclonal an-
tibodies against GII.4 noroviruses (2006-G2, G3, G4, G6, G7, NO37, NO52, and NVB 43.9) were assayed for ability to block GII.4-2012.T294P, GII.4-2012.
E368A, and GII.4-2012.09A interaction with carbohydrate ligand, and graphs representative of 2 distinct patterns are shown. The mean percentage of
control binding (percent of the VLP bound to carbohydrate ligand in the presence of an antibody compared to the amount of VLP bound with no antibody
present) of each VLP was ﬁt with a sigmoidal curve, and the mean EC50 (µg/mL) blockade titers (the antibody concentration at which 50% of VLP-PGM
binding is blocked) for GII.4-2009, GII.4-2012 VLP, GII.4-2012.T294P, GII.4-2012.E368A, and GII.4-2012.09A were calculated. Error bars represent 95% conﬁ-
dence intervals. *Mean EC50 blockade titer for the tested VLP is signiﬁcantly different from the mean EC50 for GII.4-2009 (P < .05). Monoclonal antibodies
that did not block a particular VLP at the highest mAb concentration tested were assigned an EC50 of 2 times the upper limit tested in µg/mL for statistical
analysis and are shown on the graph by data points above the upper limit of detection (dashed line). Statistics for both enzyme immunoassay and blockade
assays were calculated by 1-way analysis of variance with Dunnett posttest.
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strain is replaced by an emergent strain containing antigenic
changes facilitated by alterations in the P2 subdomain of the
norovirus capsid [5, 21, 30, 31, 33, 38]. Increased evolution of
GII.4 noroviruses over other genotypes has been correlated
with mutation rate, antigenic space, and herd immunity [39].
These antigenic changes over time have also been shown to be
speciﬁcally associated with GII.4 blockade epitopes [5–8].
These data support the hypothesis that emergence of new
strains is driven by evolutionary escape from human herd im-
munity [21, 40].
To determine if antigenic differences exist between GII.4-
2012 and the recent circulating ancestral strains GII.4-2006 and
GII.4-2009, we compared reactivity and blockade capacity
using time-ordered VLPs, mouse and human monoclonal anti-
bodies, and GII.4-2009 human outbreak convalescent sera. Of
9 tested mAbs that bind GII.4-2006 and GII.4-2009 (G2, G3,
G4, G6, G7, NO37, NVB 43.9, NVB 71.4, and NVB 97), only 4
retained the ability to react with GII.4-2012 (G2, G6, G7, and
NVB 71.4), although at signiﬁcantly lower levels compared
with GII.4-2006 and GII.4-2009. Of the 3 mouse mAbs that
reacted with GII.4-2009 and not GII.4-2006 (NO52, NO66,
NO224), 2 of them were able to react with GII.4-2012 (NO52,
NO224), albeit at signiﬁcantly reduced levels. The majority of
the tested mAbs target the A epitope, which has previously
been identiﬁed as the predominant GII.4-blockade epitope in
earlier strains. Our data also support earlier data that suggests
the presence of several overlapping epitopes within epitope
A. Epitope A–targeting mAbs, except NO52, either lost block-
ade activity or required signiﬁcantly more sera to block GII.4-
2012 ligand-binding interactions. Interestingly, whereas NO52
binding to GII.4-2012 is reduced compared to GII.4-2009, this
mAb blocks GII.4-2012 more efﬁciently than GII.4-2009. Pos-
sible explanations for this include that NO52 binding to GII.4-
2009 and GII.4-2012 may result in slightly different antibody
positioning that more efﬁciently blocks VLP-HBGA binding in
GII.4-2012, NO52 may recognize a rare overlapping epitope
that is only targeted by the immune systems of a small fraction
of the human population, or NO52 may represent a novel
mouse-speciﬁc epitope. In any event, differences among block-
ade potential of epitope A mAbs highlight the need for ﬁne res-
olution mapping of these overlapping epitopes as well as the
need for assays that measure the fraction of a polyclonal re-
sponse against a unique monoclonal antibody epitope [41].
Our mAb data clearly support the hypothesis that major anti-
genic differences exist in epitope A between GII.4-2012 and
previously circulating strains, and that this epitope may repre-
sent the major site for driving GII.4 escape from herd immuni-
ty over the past 15 years [5, 6, 8, 42].
Previous studies by our group and others support the hy-
pothesis that human immune responses may select for muta-
tions in the HBGA binding pocket, selecting for varying HBGA
recognition patterns over time in GII.4 noroviruses [5, 20, 21,
25–27]. HBGA binding assays revealed similar, but reduced
binding patterns as compared to contemporary GII.4-2006 and
2009 strains, indicating that more sophisticated measures of af-
ﬁnity binding may be needed to untangle the subtle changes in
HBGA interactions in GII.4-2012 Sydney. Supporting earlier
ﬁndings, human mAb NVB 97 completely lost reactivity and
blockade against GII.4-2012 D epitope. Epitope D minimally
consists of varying residues 393–395, but likely includes other
adjacent residues that may alter norovirus strain binding afﬁni-
ty and speciﬁcity to HBGAs as well as antibody binding and
blockade. Modulation of several residues in close proximately
to the HBGA binding pocket inﬂuence HBGA binding [6, 21,
42–44], but most of these residues have not been evaluated for
their roles in antibody binding. Overall, results from mAb
binding and blockade assays demonstrate that recognition of
epitopes A and D between GII.4-2009 and GII.4-2012 are very
different, and most neutralizing antibodies generated against
epitopes A and D during a GII.4-2009 New Orleans strain in-
fection would probably not protect against the new GII.4-2012
Sydney strain.
Blockade data from human outbreak sera also showed sig-
niﬁcant reductions in the global antibody blockade response
for GII.4-2012 compared with GII.4-2009. Importantly, a
comparison of mean outbreak human sera EC50 titers from a
Figure 7. GII.4-2012 and GII.4-2012.09A blockade by GII.4-2009 out-
break human sera. Human convalescent polyclonal sera from 8 individuals
infected in 2010 with GII.4-2009 New Orleans were assayed for ability to
block GII.4-2009, GII.4-2012, and GII.4-2012.09A virus-like particle (VLP) in-
teraction with carbohydrate ligand. The mean percentage of control
binding (percentage of the VLP bound to carbohydrate ligand in the pres-
ence of sera compared to the amount of VLP bound with no sera present)
of each VLP was ﬁt with a sigmoidal curve, and the mean EC50 (% sera)
blockade titers (the serum concentration at which 50% of VLP-PGM
binding is blocked) for GII.4-2009, GII.4-2012, and GII.4-2012.09A were
calculated. Error bars represent 95% conﬁdence intervals. *Mean EC50
blockade titer is signiﬁcantly different from the mean EC50 for GII.4-2009
(P < .05). Statistics were calculated by 1-way analysis of variance with
Dunnett posttest.
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GII.4-2009 New Orleans outbreak between GII.4-2009 and
GII.4-2012 indicate that GII.4-2012 Sydney retained only ap-
proximately 30% of the GII.4-2009 blockade response, and 2
changes in epitope A accounted for 11% of the change in block-
ade response. On an individual level, epitope A changes signiﬁ-
cantly accounted for changes in blockade response in half of
the serum samples. This suggests that individual responses to
new GII.4 strains are highly varied, and the immune response to
speciﬁc epitopes may be shaped by previous exposure history. As
GII.4 noroviruses are mucosal pathogens with short incubation
periods (<30 hours) and rapid clinical disease manifestations
(approximately 48 hours), waning immunity may rapidly permit
repeat acute infections in some but not all individuals, depending
on the speciﬁcity and afﬁnity of the global blockade speciﬁc re-
sponse to different epitopes, perhaps at both an individual and
population level. The frequency at which monoclonal antibodies
are produced against a speciﬁc epitope may be a key predictor of
short vs long-term immunity, with antibody responses to the
most frequently targeted epitopes remaining the longest and se-
lecting for the most antigenic variation. Given that the majority of
blockade monoclonal antibodies that were isolated target epitope
A, our data suggest that antibody responses against Awould wane
more slowly than antibody responses against more rarely targeted
epitopes such as D, E, and the universal epitope. Interestingly, the
ancestral blockade response against the universal neutralization
site is weak against GII.4-2012, suggesting the emergence of muta-
tions in this epitope as well. Overall, our data clearly demonstrate
that GII.4-2012 Sydney is antigenically different from both GII.4-
2006 and GII.4-2009 and support the hypothesis that emergence
of GII.4 strains is the result of escape from herd immunity as they
undergo evolution in major neutralizing epitopes.
One of the factors complicating vaccine design is the high
degree of GII.4 antigenic variation over time. Because of this
variation, the GII.4 component of a successful norovirus
vaccine will likely need to be reformulated over time. Our work
describes an important platform approach to identify GII.4
strains with pandemic potential and provides important in-
sights into effective vaccine design. We demonstrate the
importance of key reagents such as time-ordered VLPs and
monoclonal antibodies that identify surface varying residues in-
volved in escape from herd immunity. Tracking sequence and
antigenic changes over time may reveal new patterns of evolu-
tion, distinguish important overlapping epitopes, and identify
the emergence of new blockade epitopes. By identifying impor-
tant blockade epitopes for GII.4 noroviruses and tracking those
particular sites in new strains as they emerge, vaccines could be
reformulated quickly and tailored speciﬁcally to new epidemic
and pandemic strains. We may also identify important thera-
peutic antibodies targeting these epitopes in circulating strains,
which would be valuable for treating long-term chronic infec-
tions in immunosuppressed patients, as has been demonstrated
for respiratory syncytial virus [45]. In particular, our data
suggest that epitopes A and D are major drivers of escape from
herd immunity in contemporary strains, and screening new
strains for changes in these and other potential neutralization
epitopes may provide a quick and valuable method for effective
vaccine design and reformulation.
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